Berenberg analyst Luisa Hector lowered the firm’s price target on Merck (MRK) to $115 from $125 and keeps a Buy rating on the shares. Merck trades at an “unwarranted” 25% discount to the value of the company’s marketed drugs, but the pause to Gardasil shipments in China for 2025 is an :unwelcome update,” the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Trump Tariffs Are On the Table Once More for Canada & Mexico
- Eli Lilly (LLY) Commits $27B to U.S. Days after Trump Told Big Pharma to Bring Production Home or Face Tariffs
- Medicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11
- Merck’s application for keytruda in HNSCC granted priority review by FDA
- Merck & Co. Buy Rating: Strong Market Position and Growth Potential Driven by Keytruda and Promising Pipeline